Issue: March 2020

Read more

March 19, 2020
1 min read
Save

TAUSSIG

Issue: March 2020
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Tolerability and safety of evolocumab (Repatha, Amgen) in patients with severe familial hypercholesterolemia (FH).

TAUSSIG